Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lori-Ann Linkins

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
BMJ Evidence-Based Medicine|July 1, 2018
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolismLori-Ann Linkins
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 19, 2019
Shelly, MAiD and the purple paradeLori-Ann Linkins
Blood Reviews|March 12, 2013
Bleeding risks associated with vitamin K antagonistsLori-Ann Linkins
Vascular Health and Risk Management|June 20, 2008
Management of venous thromboembolism in patients with cancer: role of dalteparinLori-Ann Linkins
BMJ (Clinical Research Ed.)|January 9, 2015
Heparin induced thrombocytopeniaLori-Ann Linkins
Blood|April 23, 2016
End of the road for heparin thromboprophylaxisLori-Ann Linkins
Thrombosis and Haemostasis|January 12, 2010
High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxisJason Kerr, Lori-Ann Linkins
Current Drug Targets. Cardiovascular & Haematological Disorders|December 20, 2003
An update on new anticoagulantsLori-Ann Linkins, Jeffrey I Weitz
Current Pharmaceutical Design|November 25, 2005
Pharmacology and clinical potential of direct thrombin inhibitorsLori-Ann Linkins, Jeffrey I Weitz
Thrombosis Research|December 4, 2014
Rivaroxaban for treatment of HIT: a riveting first experienceLori-Ann Linkins, Theodore E Warkentin
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
BMJ Evidence-Based Medicine|July 1, 2018
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolismLori-Ann Linkins
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 19, 2019
Shelly, MAiD and the purple paradeLori-Ann Linkins
Blood Reviews|March 12, 2013
Bleeding risks associated with vitamin K antagonistsLori-Ann Linkins
Vascular Health and Risk Management|June 20, 2008
Management of venous thromboembolism in patients with cancer: role of dalteparinLori-Ann Linkins
BMJ (Clinical Research Ed.)|January 9, 2015
Heparin induced thrombocytopeniaLori-Ann Linkins
Blood|April 23, 2016
End of the road for heparin thromboprophylaxisLori-Ann Linkins
Thrombosis and Haemostasis|January 12, 2010
High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxisJason Kerr, Lori-Ann Linkins
Current Drug Targets. Cardiovascular & Haematological Disorders|December 20, 2003
An update on new anticoagulantsLori-Ann Linkins, Jeffrey I Weitz
Current Pharmaceutical Design|November 25, 2005
Pharmacology and clinical potential of direct thrombin inhibitorsLori-Ann Linkins, Jeffrey I Weitz
Thrombosis Research|December 4, 2014
Rivaroxaban for treatment of HIT: a riveting first experienceLori-Ann Linkins, Theodore E Warkentin
Pageof 6